|
Week 48 results (ITT-E, Missing = excluded). |
||||||
| ARV experienced |
ARV experienced |
ARV experienced |
ARV naive |
ARV naive |
ARV naive |
|
|
|
||||||
| Truvada (n = 60) |
Kivexa (n = 53) |
p-value |
Truvada (n = 64) |
Kivexa (n = 50) |
p-value |
|
|
|
||||||
| Viral load <50 copies/ml |
47/49 (95.9%) |
35/36 (97.2%) |
1.00 |
56/59 (94.9%) |
29/33 (87.9%) |
0.22 |
| Median CD4 increase (cells/mm3) |
83 |
62 |
0.36 |
208 |
170 |
0.59 |
| Withdrawn due to adverse events |
1 |
0 |
0 |
0 |
||
| Suspected ABC HSR |
0 |
0 |
0 |
1 |
||
| Proximal renal tubular dysfunction |
0 |
0 |
0 |
0 |
||
| Virological failure |
0 |
1 |
0 |
2 |
||
Eccleston et al. Journal of the International AIDS Society 2008 11(Suppl 1):P79 doi:10.1186/1758-2652-11-S1-P79 |
||||||